AZN News and Press, AstraZeneca PLC From 05/16/24

2024-05-16 10:11:45 ET More on AstraZeneca AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market AstraZeneca PLC (AZN) Q1 2024 Earnings Call Transcript AstraZeneca, Pfizer to invest combined $900M+ in France for R&D,...

2024-05-16 06:48:39 ET More on Roche Roche: Value Remains Despite Covid-19 Revenue Growth Loss Roche Holding AG (RHHBY) Q1 2024 Sales/Trading Statement Call Transcript Q1 2024 Sales/ Trading Statement Call J&J, Roche, AstraZeneca poised to have highest or...

2024-05-15 08:45:36 ET Summary Pfizer has been a losing investment for several years, but stronger trading momentum is starting to appear. An easily covered and safety-minded 6% dividend yield is very attractive today. Undervaluation arguments to own shares also exist. PFE sto...

2024-05-13 13:53:13 ET More on AstraZeneca, Pfizer Pfizer's Bottom May Be Here - Its Rich Yield Is Tempting Pfizer: A 6% Yield And At 10-Year Lows Pfizer Stock: Not A Value Trap, Here's Why Pfizer to settle over 10,000 Zantac-related cancer claims: report ...

2024-05-12 08:20:00 ET Many healthcare investors look at Johnson & Johnson (NYSE: JNJ) and see a good, safe dividend stock. But I see an investment that's full of uncertainty and risk. The company continually runs into legal problems, and I can't help but wonder if one day i...

2024-05-10 17:13:16 ET More on Bristol-Myers Squibb Company Bristol-Myers Squibb: A Lost Decade? Bristol Myers Squibb: Tough Times Continue Bristol-Myers Squibb Company (BMY) Q1 2024 Earnings Call Transcript FDA accepts Bristol Myers application for injected ...

Shares of AstraZeneca PLC (NASDAQ: AZN) traded at a new 52-week high today and are currently trading at $76.93. So far today, approximately 883.05k shares have been exchanged, as compared to an average 30-day volume of 5.67M shares. AstraZeneca PLC, a biopharmaceutical company, focuses on the...

PALM BEACH, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - There is much activity in finding better ways in mitigating muscle loss for the cancer patients… many clinical studies are looking for elite performance nutritional supplements to mitigate the m...

2024-05-08 07:06:13 ET More on AstraZeneca AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market AstraZeneca PLC (AZN) Q1 2024 Earnings Call Transcript AstraZeneca invests $140M in Cellectis, raising stake to 44% ...

2024-05-08 06:55:36 ET Summary Ascendis Pharma is expected to achieve cash flow break even by the end of 2024, driven by its core franchise of medicines for rare endocrinology conditions. The company's approved drug, Skytrofa, has shown strong sales and has the potential to be a b...